Reneo Q3 net loss $19.2M; STRIDE topline results expected December 2023

OnKure Therapeutics, Inc.

2023-Q3 EPS reported -$1.81

Net loss of $19.2M ($0.57/sh) vs $13.0M ($0.53/sh) in Q3 2022; R&D expense up to $13.6M.
Cash, cash equivalents, and short-term investments of $125.6M as of September 30, 2023.
Topline results from pivotal STRIDE study in adult PMM patients expected in December 2023.
Repurchased 576,443 shares for $4.4M from vTv Therapeutics in October 2023; shares retired.
Enrolled 88% of eligible STRIDE patients in open-label extension; 65 patients treated beyond 52 weeks.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OnKure Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $19.2 million, or $0.57 per share, EPS $0.57 per share.

Period: third quarter ended September 30, 2023
Net income: net loss of $19.2 million, or $0.57 per share
EPS: $0.57 per share
Result: reported results

Exact text from the filing

Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third quarter ended September 30, 2023

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062888

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.